Specialist Oversight for High-Complexity Radiopharma Research
UK Hospitals
Hospital Staff Relationships
Years of Experience
While our operational reach extends across various therapeutic areas, we possess a dedicated specialism in navigating the unique intricacies of cancer-focused radioisotope research. Based in the UK and operating as a global CRO, our team provides both targeted phase-specific assistance and comprehensive end-to-end management for clinical trials.
We partner with biotechs, medtech firms, and academic sponsors to execute protocols that are scientifically rigorous, logistically viable, and designed with a deep understanding of the stringent safety and regulatory demands inherent in nuclear medicine.
Navigating the Nuances of Radiopharmaceutical Studies
Clinical trials in this field are the primary engine for advancements in "theranostics" and targeted therapies for aggressive malignancies.
These protocols involve the administration of radioactive isotopes, requiring vigilant safety oversight, specialised radiation protection protocols, and the monitoring of sophisticated endpoints such as dosimetry and metabolic response.
Given the short half-life of many isotopes and the complexities of radioactive decay, study frameworks must carefully balance scientific ambition with the absolute precision required for global regulatory approval.
Expert Site Selection and Regulatory Intelligence
Navigating the site landscape for radiopharma requires a high degree of local intelligence. Through our deep-rooted experience with UK and European sites, we know exactly which units possess the necessary licensing and hot-lab infrastructure to support complex trials.
Our advantage comes from years of direct, on-the-ground collaboration. We understand the specific capacity constraints of nuclear medicine departments and can identify the sites that offer the best balance of clinical expertise and operational throughput.
By working with us, you gain access to this specific network of high-performing units, ensuring your protocol is placed at sites equipped to handle the unique storage, handling, and administration requirements of investigational radiopharmaceuticals.
Supply Chain and Dosimetry Coordination
Radiopharma trials live and die by the quality of their logistics. We specialise in synchronising high-intensity requirements, such as "just-in-time" isotope delivery, complex PET/CT or SPECT imaging, and intricate dosimetry mapping, across diverse international sites.
We act as the vital link between the sponsor, the radiopharmacy, the clinical site, and the central reading lab, ensuring that every dose is administered within the critical window and that data is captured with the mathematical precision required for targeted radiotherapy.
Frequently Asked Questions
What defines your approach to global radiopharma trials?
We combine a boutique, agile management style with a global reach. Whether we are managing a site in London or Munich, our focus remains on high-quality data and senior-level oversight. We don’t just monitor; we troubleshoot the specific logistical and regulatory challenges inherent in handling radioactive medicinal products.
How do you help sponsors identify the best European sites for radiopharma?
Because we know the UK and European sites so intimately, we guide sponsors toward locations that have the proven infrastructure to handle specific isotopes. We identify sites with the necessary certifications and the technical capacity to execute complex dosimetry protocols without delays.
Can you handle the regulatory hurdles for novel isotopes?
Yes. Our team is well-versed in the specific regulatory frameworks for radiopharmaceuticals and clinical trials of investigational medicinal products (CTIMPs). We manage the complex submissions required, ensuring that radiation safety committee approvals and site-specific licensing meet stringent international standards.
How do you ensure data quality for dosimetry and imaging?
We standardise imaging and dosimetry protocols at the outset. By working closely with site physicists, nuclear medicine technicians, and independent reading centres, we ensure that every scan is captured and analysed consistently, regardless of the geographical location of the clinic.
What makes your project teams different from a large CRO?
Continuity. You won’t deal with a revolving door of junior staff. In radiopharma, where understanding the logistics of isotope decay and complex imaging is critical, having the same senior experts from planning through to close-out prevents data errors and delays.
Do you support companies developing theranostics?
Yes. We have extensive experience with paired diagnostic and therapeutic agents. From early dose-escalation studies to larger efficacy trials, we provide the regulatory and clinical framework necessary to bring sophisticated theranostic platforms to market.
Case Study: Phase II Management of a CD8+ Imaging Tracer in Europe
We managed the European site operations for a global Phase II trial evaluating \({}^{89}\)Zr-Df-IAB22M2C, a first-in-class PET imaging agent designed to map CD8+ T-cell distribution in solid tumours.
This programme was operationally intense, requiring the precise synchronisation of radioactive payload logistics with patient imaging windows across multiple specialist oncology centres.
Our team directed the European rollout, specifically overcoming the regulatory and technical hurdles associated with the transport and handling of Zirconium-89 labelled agents.
By leveraging our established network of Tier-1 imaging units, we qualified sites with the specific PET/CT capabilities and "hot-lab" expertise necessary for sophisticated immuno-PET protocols.
Success in this radiopharmaceutical trial hinged on the seamless integration of nuclear medicine and clinical oncology departments.
We managed the complex data collection required to correlate tracer uptake with immunotherapy response, ensuring that high-frequency dosimetry and safety tracking were performed with absolute accuracy.
Our senior-led oversight of the European sites provided the sponsor with a robust, harmonised data set to validate this innovative diagnostic tool
“TCRS have provided us with a bespoke service for a complex trial in a niche product area. They have surpassed our expectations, meeting key milestones while remaining flexible in approach. I wouldn't hesitate to reach out to Peter and Davy to discuss future projects.”